ANI Pharmaceuticals (BSFA) Price & Analysis

0 Followers

BSFA Stock Chart & Stats

€70.50

€2.00(2.92%)

At close: Jul 28 4:00 PM EDT

€70.50

€2.00(2.92%)

Day’s Range― - ―

52-Week Range€54.50 - €84.00

Previous CloseN/A

Volume0.00

Average Volume (3M)0.00

Market Cap

€1.56B

Enterprise Value€1.94K

Total Cash (Recent Filing)€311.18M

Total Debt (Recent Filing)€327.76M

Price to Earnings (P/E)19.7

Beta0.27

Next Earnings

Aug 07, 2026

EPS Estimate

1.79

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)4.11

Shares Outstanding22,734,617

10 Day Avg. Volume0

30 Day Avg. Volume0

Financial Highlights & Ratios

PEG Ratio-0.05

Price to Book (P/B)2.93

Price to Sales (P/S)1.79

P/FCF Ratio10.49

Enterprise Value/Market CapN/A

Enterprise Value/RevenueN/A

Enterprise Value/Gross ProfitN/A

Enterprise Value/EbitdaN/A

Forecast

1Y Price Target

€95.73

Price Target Upside35.79% Upside

Rating ConsensusModerate Buy

Number of Analyst Covering6

EPS Forecast (FY)8.29

Revenue Forecast (FY)€983.89M

Bulls Say, Bears Say

Bulls Say

Sustained Revenue Growth & Rare Disease FocusANI's scale-up is rooted in accelerating product adoption and a durable Rare Disease mix: management expects Rare Disease to be ~60% of 2026 revenue and raised full-year guidance. Persistent tailwinds for Cortrophin and specialty commercial investments support multi‑period revenue visibility and addressable market capture.

Robust Cash Generation And Free Cash FlowConsistent, sizable operating and free cash flow enhances strategic optionality: funds organic commercial expansion, deleveraging, buybacks and BD. Strong FCF supports capital allocation choices over several years, reducing reliance on external financing during growth or integration periods.

Integrated Manufacturing & Repeat Launch CadenceIn-house manufacturing plus a steady generics launch cadence drive durable revenue diversification and higher margin capture on owned products. Vertical capabilities and consistent approvals (#2 in CGT approvals) lower dependency on single products and sustain long-term commercial momentum and gross margin potential.

Bears Say

Gross-Margin Compression And Mix RiskShift toward royalty-bearing partnered products and certain partnered launches has compressed gross margins versus prior peaks. A structurally different product mix can cap operating leverage, reduce long-term margin sustainability, and make profits more sensitive to contract terms and royalty rates.

Balance-Sheet Volatility And Historical Leverage SpikeAlthough leverage has meaningfully improved, the prior sharp spike shows the capital structure is cyclical and sensitive to operating performance. Such volatility reduces financial flexibility in downturns and raises refinancing or covenant risk if revenue or cash flow miss expectations.

Access Headwinds & Reliance On One-Time PaymentsPersistent Medicare access issues for ILUVIEN and dependence on upfront or milestone payments create structural revenue predictability risks. Reimbursement barriers slow patient uptake, while timing of nonrecurring payments increases earnings volatility and complicates multi‑period forecasting.

ANI Pharmaceuticals News

ANI Pharmaceuticals initiated with a Hold at Canaccord

Canaccord analyst Gary Nachman last night initiated coverage of ANI Pharmaceuticals (ANIP) with a Hold rating and $91...

12d ago

ANIP

ANI Pharmaceuticals intends to appeal rulings in CG Oncology matter

ANI Pharmaceuticals (ANIP) announced that Judge Sheldon K. Rennie, on July 16, denied ANI’s post-trial motions for a...

13d ago

ANIP

ANI Pharmaceuticals initiated with a Hold at Canaccord

Canaccord initiated coverage of ANI Pharmaceuticals (ANIP) with a Hold rating and $91 price target Published first on...

13d ago

ANIP

ANI Pharmaceuticals reports ‘positive’ results from Phase 4 Synchronicity trial

ANI Pharmaceuticals (ANIP) announced positive topline data from its Phase 4, open-label, single-arm Synchronicity clinical trial of Fluocinolone...

16d ago

ANIP

Buy Rating Reaffirmed on Cortrophin Strength and ILUVIEN Upside; $121 Price Target Maintained

Analyst Brandon Folkes from H.C. Wainwright maintained a Buy rating on ANI Pharmaceuticals and keeping the price target...

16d ago

ANIP

ANI Pharmaceuticals Signals Confident 2026 Growth Path

Ani Pharmaceuticals (($ANIP)) has held its Q1 earnings call. Read on for the main highlights of the call....

2M ago

ANIP

ANI Pharmaceuticals Shareholders Approve Amended 2022 Incentive Plan

ANI Pharmaceuticals ( ($ANIP) ) just unveiled an update. ANI Pharmaceuticals, Inc. held its 2026 Annual Meeting of...

2M ago

ANIP

ANI Pharmaceuticals Updates Investor Presentation, Highlights Non-GAAP Metrics

ANI Pharmaceuticals ( ($ANIP) ) has provided an update. On May 13, 2026, ANI Pharmaceuticals, Inc. published an...

3M ago

ANIP

Analyst Reiterates Buy Rating After Earnings Beat and Raised Full-Year Guidance on Strong Cortrophin Gel Momentum

J.P. Morgan analyst has maintained their bullish stance on ANIP stock, giving a Buy rating on May 8....

3M ago

ANIP

ANI Pharmaceuticals reports Q1 non-GAAP EPS $2.05, consensus $1.30

Reports Q1 revenue $237.46M, consensus $207.63M. “We delivered a strong first quarter, generating $237.5M in revenue and $63.0M...

3M ago

ANIP

ANI raises FY26 adjusted EPS view to $9.19-$9.69 from $8.83-$9.34

Raises FY26 revenue view to $1.080B-$1.140B from $1.055B-$1.115B. Consensus is for FY26 EPS $9.07 and for revenue $1.09B....

3M ago

ANIP

ANIP Earnings Report this Week: Is It a Buy, Ahead of Earnings?

Ani Pharmaceuticals (ANIP) is scheduled to report 1st quarter earnings on 05/08/2026, before the market opens. Regarding Q1...

3M ago

ANIP

ANI Pharmaceuticals announces FDA approval, launch of Pimozide Tablets

ANI Pharmaceuticals (ANIP) announced the launch of Pimozide Tablets 1 mg and 2 mg. ANI’s Pimozide Tablets is...

3M ago

ANIP

ANI Pharmaceuticals launches Isosorbide Mononitrate Tablet USP

ANI Pharmaceuticals (ANIP) announced that following final approval from the FDA for its Abbreviated New Drug Application, or...

4M ago

ANIP

BSFA FAQ

What was ANI Pharmaceuticals Inc’s price range in the past 12 months?

ANI Pharmaceuticals Inc lowest stock price was €54.50 and its highest was €84.00 in the past 12 months.

What is ANI Pharmaceuticals Inc’s market cap?

ANI Pharmaceuticals Inc’s market cap is €1.56B.

When is ANI Pharmaceuticals Inc’s upcoming earnings report date?

ANI Pharmaceuticals Inc’s upcoming earnings report date is Aug 07, 2026 which is in 9 days.

How were ANI Pharmaceuticals Inc’s earnings last quarter?

ANI Pharmaceuticals Inc released its earnings results on May 08, 2026. The company reported €1.8 earnings per share for the quarter, beating the consensus estimate of €1.14 by €0.659.

Is ANI Pharmaceuticals Inc overvalued?

According to Wall Street analysts ANI Pharmaceuticals Inc’s price is currently Undervalued. Get more investment ideas with TipRanks Premium

Does ANI Pharmaceuticals Inc pay dividends?

ANI Pharmaceuticals Inc does not currently pay dividends.

What is ANI Pharmaceuticals Inc’s EPS estimate?

ANI Pharmaceuticals Inc’s EPS estimate is 1.79.

How many shares outstanding does ANI Pharmaceuticals Inc have?

ANI Pharmaceuticals Inc has 22,734,617 shares outstanding.

What happened to ANI Pharmaceuticals Inc’s price movement after its last earnings report?

ANI Pharmaceuticals Inc reported an EPS of €1.8 in its last earnings report, beating expectations of €1.14. Following the earnings report the stock price went down -1.408%.

Which hedge fund is a major shareholder of ANI Pharmaceuticals Inc?

Currently, no hedge funds are holding shares in DE:BSFA

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

ANI Pharmaceuticals Stock Smart Score

Neutral

Fundamentals

Return on Equity

―

Trailing 12-Months

Asset Growth

10.02%

Trailing 12-Months

Top Smart Score Stocks >

Company Description

ANI Pharmaceuticals Inc

ANI Pharmaceuticals, Inc., a biopharmaceutical company, develops, manufactures, and markets branded and generic pharmaceutical products in the United States and internationally. The company provides injectables, softgel capsules, and Cortrophin gel, as well as ILUVIEN and YUTIQ products. It also manufactures oral solid dose products, semi-solids, liquids, topicals, controlled substances, and potent products. The company serves its products to national wholesalers, specialty pharmacies, retail pharmacy chains, distributors, mail order houses, group purchasing organizations, and hospitals and healthcare providers. ANI Pharmaceuticals, Inc. was incorporated in 2001 and is headquartered in Baudette, Minnesota.

ANI Pharmaceuticals (BSFA) Earnings & Revenues

Historic Earnings Reports

BSFA Company Deck

BSFA Earnings Call

Q1 2026

0:00 / 0:00

Earnings Call Sentiment|Positive

The call conveyed strong operational momentum and material financial progress: consolidated Q1 revenue growth (20% YoY), Cortrophin Gel growth (42% YoY), adjusted EBITDA and EPS expansion, raised 2026 guidance, near-term cash from an IP out-license, an active product launch cadence in Generics, and a sizeable commercial expansion into acute gouty arthritis flares. Offsetting items include margin pressure from a higher mix of royalty-bearing products and new launches, temporary insurance reverification and access headwinds that impacted Q1 timing, increased SG&A from sales expansion, and some reliance on timing of upfront/milestone payments. Overall, positives (revenue/EBITDA growth, guidance raise, strategic investments and M&A optionality, cash position, repurchase program) materially outweigh the lowlights (margin compression, access and timing issues), supporting a constructive outlook for 2026 and into 2027.View all DE:BSFA earnings summaries

BSFA Stock 12 Month Forecast

Average Price Target

€95.73

▲(35.79% Upside)

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"53":"€53","67":"€67","81":"€81","95":"€95","109":"€109"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":108.9094046,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">€108.91</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":95.73487985,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">€95.73</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":79.92545015,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">€79.93</span>\n  </div></div>","useHTML":true}}],"tickPositions":[53,67,81,95,109],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Oct<br/>2025","6":"Jan<br/>2026","9":"Apr<br/>2026","12":"Jul<br/>2026","25":"Jul<br/>2027"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,72.5,75.30072343076922,78.10144686153846,80.90217029230769,83.70289372307693,86.50361715384615,89.30434058461539,92.10506401538461,94.90578744615385,97.70651087692308,100.50723430769231,103.30795773846154,106.10868116923078,{"y":108.9094046,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,72.5,74.28729845,76.0745969,77.86189535,79.6491938,81.43649225,83.2237907,85.01108915,86.7983876,88.58568604999999,90.3729845,92.16028295,93.9475814,{"y":95.73487985,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,72.5,73.07118847307693,73.64237694615385,74.21356541923078,74.78475389230769,75.35594236538462,75.92713083846154,76.49831931153847,77.06950778461538,77.64069625769231,78.21188473076923,78.78307320384616,79.35426167692307,{"y":79.92545015,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":54,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 11,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 14, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":54.5,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 17,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 14, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":78.5,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 22,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 14, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":75.5,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 16,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 7, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":77.5,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 10,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 10, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":71.5,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 8, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":68,"date":1767225600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 11,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 9, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":68,"date":1769904000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 21,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 28, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":64,"date":1772323200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 23,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 29, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":65.5,"date":1775001600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 17,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 26, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":67.5,"date":1777593600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 15,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 7, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":65.5,"date":1780272000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 17,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 7, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":72.5,"date":1782864000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 33,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 11, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Detailed Analyst Forecast >